Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
PPH vs VHT: Weighing Concentrated Pharma Exposure Against Broad Health Care Sector Diversification

PPH vs VHT: Weighing Concentrated Pharma Exposure Against Broad Health Care Sector Diversification

Key Takeaways

  • PPH (PPH) is a concentrated, global pharmaceutical fund of roughly 25 holdings, while VHT (VHT) spans the entire U.S. health care sector with more than 400 holdings.
  • Cost structure diverges sharply: PPH charges a 0.36% expense ratio versus 0.09% for VHT, a meaningful advantage for long-term, cost-conscious investors.
  • PPH is heavily driven by a handful of large-cap drug makers and carries single-stock concentration risk, while VHT smooths exposure across pharmaceuticals, biotech, medical devices, insurers, and providers.
  • Both funds are passively managed and fully investable through the same broad health care theme, but they represent different risk and diversification profiles rather than direct substitutes.
  • Tickeron AI Verdict: VHT — its superior diversification, lower cost, and broader sector footprint give it the structural edge in the current environment.

Introduction

Investors evaluating the health care space often face a choice between a pure-play pharmaceutical strategy and a wider sector approach. That distinction is at the heart of comparing PPH and VHT. These ETFs do not target the exact same niche; instead, they provide different routes into a common investment area. PPH focuses on large-cap global drug makers, whereas VHT covers the full U.S. health care sector, including drug manufacturers, insurers, and equipment suppliers. With an aging population, shifting drug-pricing rules, and innovation in areas such as weight-loss therapies influencing the landscape, comparing the two helps clarify whether concentration or diversification aligns better with specific objectives.

VanEck Pharmaceutical ETF (PPH) Overview

The VanEck Pharmaceutical ETF (PPH) aims to track the MVIS US Listed Pharmaceutical 25 Index, which follows the largest and most liquid U.S.-listed pharmaceutical companies. The fund typically holds around 25 positions, resulting in a concentrated, non-diversified structure. It applies a modified market-cap weighting approach with a single-issuer cap, and the index undergoes semi-annual reviews with quarterly rebalancing. Top holdings include LLY (Eli Lilly), MRK (Merck), NVS (Novartis), NVO (Novo Nordisk), and PFE (Pfizer), along with names such as BMY (Bristol-Myers Squibb), MCK (McKesson), and GSK. Sector allocation sits at essentially 100% health care, with notable international exposure via U.S.-listed foreign drug makers. The expense ratio stands at 0.36%, and the fund launched in December 2011. Its core characteristic is a focused, high-conviction position in leading pharmaceutical companies. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.

Vanguard Health Care ETF (VHT) Overview

The Vanguard Health Care ETF (VHT) follows the MSCI US Investable Market Index (IMI) Health Care 25/50, encompassing large-, mid-, and small-cap U.S. health care companies. With more than 400 holdings, it delivers a broad, market-cap-weighted view of the entire sector. Vanguard uses a passively managed, full-replication strategy, resorting to sampling only when regulatory limits require it. Top holdings include LLY (Eli Lilly), JNJ (Johnson & Johnson), ABBV (AbbVie), MRK (Merck), and UNH (UnitedHealth Group), followed by TMO (Thermo Fisher), AMGN (Amgen), GILD (Gilead), and ABT (Abbott). This composition includes not only drug makers but also insurers, device manufacturers, and service providers. The fund charges 0.09% and has been in operation since January 2004, positioning it as one of the more established and cost-efficient health care ETFs available.

Industry and Thematic Backdrop

Both ETFs operate in a health care sector supported by long-term growth drivers alongside occasional policy uncertainties. Demand for medical innovation stays robust, with investor focus on metabolic and obesity treatments, oncology pipelines, and immunology products. At the same time, U.S. drug-pricing changes, patent expirations, and examination of pharmacy-benefit and insurer practices add regulatory variables. Capital has tended to favor diversified, defensive health care exposure during economic uncertainty, while momentum can shift toward pure pharma when major drug developments dominate attention. This setting favors investors who recognize whether they are accepting concentrated pharmaceutical risk or broader sector exposure.

Performance and Positioning Comparison

In recent cycles, PPH and VHT have often moved in tandem due to their shared emphasis on mega-cap drug makers such as Eli Lilly, yet their risk characteristics differ in important ways. PPH’s concentrated portfolio makes returns more responsive to earnings cycles, pipeline updates, and clinical-trial results from a limited set of large pharmaceutical names. VHT, on the other hand, combines pharmaceutical exposure with more defensive areas such as managed care, medical devices, and diversified health care services, which can moderate volatility during sector-wide declines. Historically, VHT has shown a lower beta and a steadier drawdown profile, while PPH provides greater potential sensitivity when large-cap pharma leadership strengthens. For positioning purposes, VHT’s breadth and lower cost support its role as a steadier core holding, whereas PPH serves better as a tactical, high-conviction addition. From what I see, this distinction becomes especially relevant when assessing how each fund might behave in varying market conditions.

Exploring AI Tools for ETF Analysis

When evaluating sector-specific ETFs like these, I find it helpful to cross-reference data with analytical platforms. Tickeron’s AI tools can assist in identifying patterns and comparing holdings across similar funds, offering an additional layer of insight during the research process.

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI currently favors VHT. Its wider diversification across more than 400 holdings reduces single-stock and single-subindustry concentration risk, while the 0.09% expense ratio delivers cost efficiency that compounds over time. VHT’s exposure to defensive segments such as managed care and medical devices supports more consistent trend behavior and lower relative volatility, and its established track record and liquidity strengthen its case as a durable core allocation. PPH continues to offer appeal as a tactical vehicle for investors seeking concentrated pharmaceutical momentum, but overall the combination of cost advantage, diversification, and smoother risk-adjusted positioning gives VHT the edge in the current environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PPH, VHT

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


PPH in -3.06% downward trend, declining for three consecutive days on November 18, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PPH declined for three days, in 247 of 312 cases, the price declined further within the following month. The odds of a continued downward trend are 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PPH moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 27 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 65 cases where PPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PPH as a result. In 67 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.

The Moving Average Convergence Divergence Histogram (MACD) for PPH turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 32 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 65%.

PPH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

PPH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PPH crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.

Following a +0.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPH advanced for three days, in 282 of 343 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

The Aroon Indicator entered an Uptrend today. In 253 of 297 cases where PPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), McKesson Corp (NYSE:MCK), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN).

Industry description

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Market Cap

The average market capitalization across the VanEck Pharmaceutical ETF (PPH) ETF is 173.41B. The market cap for tickers in the group ranges from 2.2B to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is PRGO at 2.2B.

High and low price notable news

The average weekly price growth across all stocks in the VanEck Pharmaceutical ETF (PPH) ETF was 4%. For the same ETF, the average monthly price growth was 33%, and the average quarterly price growth was 56%. ZTS experienced the highest price growth at 4%, while DFTX experienced the biggest fall at -16%.

Volume

The average weekly volume growth across all stocks in the VanEck Pharmaceutical ETF (PPH) ETF was 30%. For the same stocks of the ETF, the average monthly volume growth was 25% and the average quarterly volume growth was 32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 50
Price Growth Rating: 39
SMR Rating: 59
Profit Risk Rating: 52
Seasonality Score: 18 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.